Comparative Pharmacology
Head-to-head clinical analysis: LOESTRIN 21 1 5 30 versus NORINYL 1 35 21 DAY.
Peer-Reviewed Evidence
Head-to-head clinical analysis: LOESTRIN 21 1 5 30 versus NORINYL 1 35 21 DAY.
LOESTRIN 21 1.5/30 vs NORINYL 1+35 21-DAY
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Combination estrogen-progestin contraceptive: suppresses gonadotropin release, inhibiting ovulation; increases viscosity of cervical mucus, impeding sperm penetration; alters endometrial morphology.
Combination oral contraceptive containing norethindrone (progestin) and ethinyl estradiol (estrogen). Suppresses gonadotropin release (FSH, LH) via negative feedback on hypothalamic-pituitary-ovarian axis, inhibiting ovulation. Increases cervical mucus viscosity and alters endometrial structure to impair sperm penetration and implantation.
One tablet (norethindrone acetate 1.5 mg/ethinyl estradiol 30 mcg) orally once daily for 21 consecutive days, followed by 7 days off therapy.
One tablet orally once daily for 21 consecutive days, followed by 7 days off therapy.
None Documented
None Documented
Ethinyl estradiol: ~12-14 h; Norethindrone: ~5-12 h. Steady-state achieved in ~5-10 days.
Norethindrone: 7-8 hours; Ethinyl estradiol: 13-27 hours (mean ~17 hours). Steady state achieved by day 10-14.
Primarily hepatic metabolism; ~40-60% renal, 20-30% biliary/fecal.
Renal (50-60% as metabolites, primarily glucuronide and sulfate conjugates) and fecal (30-40% as metabolites). Less than 1% excreted unchanged.
Category C
Category C
Combined Oral Contraceptive
Combined Oral Contraceptive